Jiangsu Aidea Pharmaceutical Co., Ltd.

SHSE:688488 Stock Report

Market Cap: CN¥3.5b

Jiangsu Aidea Pharmaceutical Past Earnings Performance

Past criteria checks 0/6

Jiangsu Aidea Pharmaceutical's earnings have been declining at an average annual rate of -57.1%, while the Biotechs industry saw earnings growing at 7.6% annually. Revenues have been growing at an average rate of 5.6% per year.

Key information

-57.1%

Earnings growth rate

-58.6%

EPS growth rate

Biotechs Industry Growth11.3%
Revenue growth rate5.6%
Return on equity-9.1%
Net Margin-25.6%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Unpleasant Surprises Could Be In Store For Jiangsu Aidea Pharmaceutical Co., Ltd.'s (SHSE:688488) Shares

Oct 16
Unpleasant Surprises Could Be In Store For Jiangsu Aidea Pharmaceutical Co., Ltd.'s (SHSE:688488) Shares

Jiangsu Aidea Pharmaceutical Co., Ltd.'s (SHSE:688488) 30% Share Price Plunge Could Signal Some Risk

Jun 29
Jiangsu Aidea Pharmaceutical Co., Ltd.'s (SHSE:688488) 30% Share Price Plunge Could Signal Some Risk

Jiangsu Aidea Pharmaceutical (SHSE:688488) Is Making Moderate Use Of Debt

Jun 07
Jiangsu Aidea Pharmaceutical (SHSE:688488) Is Making Moderate Use Of Debt

Jiangsu Aidea Pharmaceutical Co., Ltd.'s (SHSE:688488) Shares Climb 27% But Its Business Is Yet to Catch Up

Mar 01
Jiangsu Aidea Pharmaceutical Co., Ltd.'s (SHSE:688488) Shares Climb 27% But Its Business Is Yet to Catch Up

Revenue & Expenses Breakdown

How Jiangsu Aidea Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SHSE:688488 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24409-10521286
30 Jun 24354-11220180
31 Mar 24392-9020471
31 Dec 23411-7620363
30 Sep 23412-8020952
30 Jun 23409-6620964
31 Mar 23322-10119360
31 Dec 22244-12417664
30 Sep 22180-11414971
30 Jun 22172-11112558
31 Mar 22213-649953
31 Dec 21256-308648
30 Sep 21309178039
30 Jun 21317288437
31 Mar 21322488431
31 Dec 20289408026
30 Sep 20327518230
30 Jun 20311427227
31 Mar 20309317326
31 Dec 19345348128
31 Dec 1827797534
31 Dec 17136-384434

Quality Earnings: 688488 is currently unprofitable.

Growing Profit Margin: 688488 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 688488 is unprofitable, and losses have increased over the past 5 years at a rate of 57.1% per year.

Accelerating Growth: Unable to compare 688488's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 688488 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (1.3%).


Return on Equity

High ROE: 688488 has a negative Return on Equity (-9.14%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 12:35
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Jiangsu Aidea Pharmaceutical Co., Ltd. is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yuan Yuan SunIndustrial Securities Co. Ltd.
Song YangTianfeng Securities Brokerage Co., Ltd